Brawn Biotech Limited reported a net profit of ₹15.44 lakh for the quarter ended June 30, 2026, down from ₹23.60 lakh in the corresponding period of FY25. While revenue from operations grew modestly to ₹607.88 lakh from ₹579.77 lakh year-ago, the profitability contraction highlights pressure on operating efficiency.

The board of directors approved the unaudited financial results on August 13, 2026, following recommendations from the Audit Committee. The company also recommended the appointment of M/s G D S M and Co as statutory auditors for a five-year term, subject to shareholder approval at the upcoming Annual General Meeting (AGM).

Financial Performance

Revenue from operations increased by 4.8% year-on-year. However, total expenses rose sharply to ₹606.30 lakh from ₹565.26 lakh in Q1FY25, largely due to significant changes in inventory levels.

What the Numbers Show

A divergence between revenue growth and expense inflation is visible in the data. While revenue rose by just under 5%, total expenses climbed by over 7%. This was primarily driven by a surge in "Change in inventories" to ₹295.34 lakh from ₹104.92 lakh in the prior year quarter. This indicates that a significant portion of the cost outflow was tied to inventory accumulation rather than direct consumption or sales, compressing the profit from operations before tax to ₹15.44 lakh from ₹23.60 lakh.

Corporate Actions

Alongside the financial results, the board approved the convening of the 41st Annual General Meeting via Video Conferencing/Other Audio-Visual Means on September 29, 2026. The draft notice for the AGM will be dispatched to shareholders shortly.

The company engaged Rajiv Udai & Associates to conduct the limited review of the interim financial information. The CFO certificate confirmed no material changes in internal controls or instances of fraud during the quarter.

Brawn Biotech Limited returned to profitability in the financial year ended March 31, 2026, posting a net profit of ₹94.06 lakh compared to a net loss of ₹179.81 lakh in the previous year. The company’s revenue from operations for FY26 stood at ₹1,697.77 lakh. The Board of Directors approved the audited financial results for the quarter and year ended March 31, 2026, at its meeting held on May 29, 2026.

For the quarter ended March 31, 2026, the company reported a net profit of ₹58.34 lakh. Revenue from operations for the quarter was ₹197.65 lakh. Total comprehensive income for the year increased to ₹97.71 lakh from a negative ₹176.08 lakh in the prior year. The earnings per share (EPS) for the year improved to ₹3.26 from a negative ₹5.87 in the previous year.

Financial Performance

The company’s total expenses for the year amounted to ₹1,743.07 lakh, slightly higher than the total revenue of ₹1,743.18 lakh. Profit from operations before other income and exceptional items was nominal at ₹0.11 lakh for the year. The statutory auditors, M/s Rajiv Udai & Associates, issued an unmodified opinion on the standalone financial results.

Key Financial Metrics

Balance Sheet Highlights

The company’s total assets as of March 31, 2026, were ₹2,085.72 lakh, compared to ₹2,048.90 lakh in the previous year. Total equity increased to ₹433.94 lakh from ₹336.23 lakh. Current assets stood at ₹1,711.99 lakh, while current liabilities were reported at ₹1,517.02 lakh.

The financial results were reviewed by the Audit Committee and are in compliance with the Indian Accounting Standards (Ind AS). The company is primarily engaged in the pharmaceuticals business and has no separate reportable segments as per Ind-AS 108.